Edesa Biotech filings document the formal disclosure record of a clinical-stage biotechnology issuer focused on host-directed therapeutics for immuno-inflammatory diseases. Recent Form 8-K reports cover clinical-study disclosures for paridiprubart in Acute Respiratory Distress Syndrome, operating and financial results, material-event updates and agreements connected to funded development work.
The company’s filings also address capital-structure matters, including common-share sales under at-the-market offering arrangements and related Form S-3 prospectus supplements. Proxy materials cover shareholder voting matters, board governance, executive compensation and equity-award disclosures for the public company.
Edesa Biotech, Inc. (EDSA) entered into an underwriting agreement with Guggenheim Securities for a primary underwritten, registered offering of (i) 3,870,500 common shares with accompanying common share warrants and (ii) pre-funded warrants to purchase up to 675,000 common shares with accompanying common share warrants. Each common share plus warrant unit is priced at $5.50, and each pre-funded warrant plus warrant unit at $5.4999.
The common share warrants have a $7.50 exercise price and expire on the earlier of 18 months from issuance or 30 days after Edesa publicly announces Phase 2 vitiligo topline data for EB06. Gross proceeds are expected to be about $25.0 million and net proceeds about $23.1 million, with a 30‑day underwriters’ option for up to 681,825 additional shares and warrants. Edesa plans to use proceeds for general corporate purposes, including working capital, capital expenditures, and research and development and manufacturing expenses.
Edesa Biotech, Inc. (EDSA) is conducting a follow‑on offering of 3,870,500 common shares and, for certain investors in lieu of shares, pre‑funded warrants to purchase up to 675,000 common shares, together with common share warrants to purchase up to 4,545,500 common shares.
The securities are priced at a combined public offering price of $5.50 per common share and accompanying warrant (or $5.4999 per pre‑funded warrant and accompanying warrant), for total gross proceeds of $25.0 million and underwriting discounts of $1.5 million. Estimated net proceeds are about $23.1 million, to be used for general corporate purposes including working capital, R&D and manufacturing.
The common share warrants are exercisable at $7.50 per share and expire on the earlier of 18 months after issuance or 30 days following public announcement of Phase 2 vitiligo topline data for EB06. The pre‑funded warrants are immediately exercisable at $0.0001 per share and do not expire. The offering will dilute new investors by $3.28 per share relative to the $5.50 offering price.
Edesa Biotech, Inc. (EDSA) plans a primary offering of common shares, pre-funded warrants and common share warrants under an effective shelf registration. Each common share (or pre-funded warrant) will be sold together with an accompanying common share warrant, with all securities issued separately but purchased together.
The company expects to use net proceeds for general corporate purposes, including working capital, capital expenditures, and research and development and manufacturing expenses. As of June 30, 2026, Edesa Biotech had 9,633,223 common shares outstanding and net tangible book value of $6.9 million, or $0.72 per share, and discloses that investors in this offering will experience dilution relative to this book value.
Edesa Biotech, Inc. reported larger losses for the quarter and nine months ended June 30, 2026 while advancing its inflammatory and immune‑related drug pipeline. Net loss was $5.4 million for the quarter and $11.9 million for the nine months, compared with $1.7 million and $5.0 million in the prior‑year periods, driven mainly by higher research and development spending on vitiligo candidate EB06 and respiratory candidate paridiprubart.
R&D expenses rose to $3.96 million in the quarter and $7.85 million year‑to‑date, while cash used in operating activities increased to $7.2 million for the nine months. Edesa ended the period with $10.3 million in cash and cash equivalents, working capital of $6.9 million, and an accumulated deficit of $77.9 million. The company disclosed a material uncertainty about its ability to continue as a going concern and expects existing resources, potential ATM sales, and Canadian SRF reimbursements will not fund operations, including the vitiligo program, through fiscal 2026 without additional financing.
Edesa highlighted progress in its pipeline, including regulatory readiness for a Phase 2 EB06 vitiligo study and prior positive Phase 3 data for paridiprubart in ARDS. It also benefits from up to C$23 million in partially repayable Canadian government Strategic Response Fund support and recently raised capital via ATM sales and a June 2026 private placement.
Edesa Biotech, Inc. reported fiscal third-quarter 2026 results and business updates. The company completed preparations for a Phase 2 clinical study of EB06 for moderate-to-severe vitiligo and began activating investigational sites after quarter-end, with initial recruitment expected in Canada, followed by additional jurisdictions subject to regulatory approvals.
In its respiratory program, exploratory analyses in ARDS patients with concurrent acute kidney injury associated paridiprubart plus standard of care with mortality reductions and improvements in the kidney-specific MAKE30 composite endpoint, and Edesa is evaluating regulatory pathways and strategic options. Financially, total operating expenses for the quarter rose to $5.5 million from $1.9 million a year earlier, driven mainly by higher R&D spending on EB06 and increased general and administrative costs. Net loss for the quarter widened to $5.4 million, or $0.60 per share, from $1.7 million, or $0.25 per share. For the nine months ended June 30, 2026, net loss was $11.9 million versus $5.0 million in the prior-year period. At June 30, 2026, Edesa held $10.3 million in cash and cash equivalents and reported working capital of $6.9 million.
Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech, Inc. Chief Executive Officer and 10% owner Pardeep Nijhawan received a grant of 5,324 restricted share units on 2026-08-03, vesting in full upon grant under the 2019 Equity Incentive Compensation Plan. After this award, he directly holds 893,386 common shares, plus additional indirect holdings through affiliated entities and a family trust, for which he disclaims beneficial ownership beyond his pecuniary interest.
Edesa Biotech, Inc. is registering up to 729,241 common shares for resale by existing investors who acquired these shares in a June 2026 private placement. This is a resale registration only; Edesa will not receive any proceeds from sales made under this prospectus, though it has borne the registration costs.
In the private placement, institutional and accredited investors, including the chief executive officer, purchased an aggregate of $3.5 million of common shares at $4.69 per share for outside investors and $5.21 per share for the CEO. Edesa previously stated it intends to use those net proceeds to advance its vitiligo program and its respiratory drug candidate paridiprubart, and for working capital and general corporate purposes.
Edesa is a biopharmaceutical company focused on inflammatory and immune-related diseases, with programs in medical dermatology (including vitiligo and allergic contact dermatitis) and respiratory conditions such as acute respiratory distress syndrome. As of June 17, 2026, it had 9,633,223 common shares outstanding and listed its common shares on the Nasdaq Capital Market under the symbol EDSA.
Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech Chief Executive Officer Pardeep Nijhawan reported a compensation-related stock grant. He received 3,378 restricted share units of Edesa Biotech common shares at no cost, which vested in full upon grant under the company’s 2019 Equity Incentive Compensation Plan.
Following this award, he directly holds 888,062 common shares. The filing also lists indirect common share holdings held through entities such as Pardeep Nijhawan Medicine Professional Corporation, 1968160 Ontario Inc., The Digestive Health Clinic Inc., and The New Nijhawan Family Trust 2015, for which he reports positions but disclaims full beneficial ownership beyond his pecuniary interest.
Edesa Biotech, Inc. registers for resale up to 729,241 common shares issued in a private placement closed June 16, 2026.
The prospectus states these Shares were sold at $4.69 per share to Purchasers (and $5.21 per share to the CEO) for aggregate proceeds of approximately $3.5 million, and that the Company will not receive any proceeds from subsequent resales. Shares outstanding were 9,633,223 as of June 17, 2026.